CA-MAANA
5.12.2018 02:37:04 CET | Business Wire | Press release
Maana, the pioneer of digital knowledge technology, announced the expansion of its international operations with the opening of its London office. Marking the company’s fifth location since its beginnings in 2013, the UK headquarters is located at One Canada Square, an iconic building residing in Canary Wharf – a rich cultural district housing several Fortune Global 500 listed corporations.
This expansion highlights the market’s response to Maana’s solution, the Knowledge Platform, which enables industrial organizations to accelerate decision making across the enterprise, gaining operational efficiencies and resulting in considerable CAPEX and OPEX improvements.
“We are excited to be working with the industry’s top leaders - the catalysts for change - who are breaking the barriers of data and organizational silos so that their enterprises can realize the benefits of a fully digitalized infrastructure,” said Maana Founder and CEO, Babur Ozden. “From our new London office, we will support our growing customer base in Europe and have access to top talent to grow our organization.”
The London operations augment Maana’s existing presence in Palo Alto, California; Bellevue, Washington; Houston, Texas and Dhahran, Saudi Arabia and is home to Maana’s team of experts who have implemented groundbreaking business applications and solutions for companies like IBM, Cisco, Romonet and Elsevier.
“London is a critical hub for the global energy sector and a large segment of our international industrial clients,’ said Kieran O’Byrne, a Principal Customer Solutions Analyst who previously worked for IBM driving the adoption of IBM Watson technologies. “I’m happy to join Maana’s accomplished team of London-based data scientists and customer solutions team members. This marquee location will only further our recruitment activities and will help our customer’s digital transformation journeys.”
About Maana:
Maana is an award-winning digital knowledge platform provider focused on creating CAPEX and OPEX gains for industrial companies. Its unique Computational Knowledge Graph ™ de-silos knowledge from data sources and tacit expertise, to improve decision making across the enterprise. Maana’s investors include Intel Capital, GE Ventures, Chevron Technology Ventures, Saudi Aramco Energy Ventures, Shell Technology Ventures, Accenture Ventures, and China International Capital Corporation.
Maana is privately held with offices in Palo Alto, California; Bellevue, Washington; Houston, Texas, London, UK; and Dhahran, Saudi Arabia. Visit us at https://www.maana.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204006195/en/
Contact:
Linda Madden lmadden@piercom.com (713) 627-2223
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 15:30:00 CEST | Press release
Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet needThe collaboration will augment Merck’s efforts to pursue precision medicine-defined indicationsNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Resea
Beyond the ‘Dumb Pipe’: How Agentic AI and Sovereign Networks Are Redefining Connectivity23.6.2026 14:46:00 CEST | Press release
The global connectivity market is shifting. With traditional European telecom growth slowing to 2-3% by 2029, businesses must adapt through Agentic AI, critical communications, and digital sovereignty. To remain competitive, operators should move beyond infrastructure toward an API-driven economy. These trends took center stage at Comarch User Group 2026. The conference hosted over 700 partners from 53 countries, including 201 connectivity experts, highlighting how companies can thrive in regulated environments. As telecom growth slows, demand for broader connectivity solutions across satellite, logistics, and critical communications is surging. Operators must abandon the old 4G “dumb pipe” model, where they act merely as network providers charging only for raw data transmission, for an API-driven economy with programmable network quality, securely integrating 5G with new satellite and IoT ecosystems. - Marcin Kaleta, CEO at Comarch Communications Putting Agentic AI in the Driver's Sea
Mary Kay Extends Winning Streak With Fourth Year as #1 in Global Direct Selling Beauty23.6.2026 14:03:00 CEST | Press release
Euromonitor International Recognizes Mary Kay’s Sustained Leadership In Skin Care And Color Cosmetics Mary Kay Inc., the iconic beauty and entrepreneurship company, has once again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International, sustaining its legacy of excellence for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623487381/en/ Mary Kay Inc., the iconic beauty and entrepreneurship company, for the fourth year in a row has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International. (Image Credit: Mary Kay Inc.) “Earning the #1 global ranking from Euromonitor for the fourth consecutive year comes as a powerful endorsement of the impact of our Independent Beauty Consultants around the world who drive our success every day,” said Ryan Rogers, Chief Executive Officer of Mary Kay
Kobie 2026 Heart of Loyalty Report Reveals Growing Gap Between Consumer Expectations and Brand Loyalty Strategies23.6.2026 14:00:00 CEST | Press release
Global study finds consumers are more ready for AI, more willing to share data, and more motivated by recognition and shared values than many brands realize Kobie, a global leader in loyalty technology and services, today released its 2026 Heart of Loyalty Report, which surveyed both consumers and practitioners, revealing significant gaps between consumer expectations and brand loyalty strategies across AI adoption, data sharing, recognition, advocacy, and community engagement. Kobie's 2026 Heart of Loyalty Report found that: 57% of consumers are willing to engage with AI-powered brand experiences, yet 56% of loyalty practitioners believe customers are not ready for AI. 77% of consumers want recognition from brands, but only 55% feel seen as individuals. 72% of consumers say they would refer a brand without an incentive, yet many referral strategies remain heavily dependent on rewards. Rewards are the strongest driver of willingness to share personal data, yet only 65% of practitioners
Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release
Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom